Aummune
Tel Aviv, Israel· Est.
Personalized tri‑functional oligonucleotide immunotherapy for solid tumors.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Personalized tri‑functional oligonucleotide immunotherapy for solid tumors.
Oncology
Technology Platform
Tri‑functional oligonucleotide platform that assembles a tumor‑targeting aptamer, a CpG bridge, and a T‑cell engaging strand to induce cancer cell death and activate innate and adaptive immunity.
Opportunities
Scalable personalized immunotherapy platform targeting a broad range of solid tumors, with potential for rapid expansion into additional indications and combination regimens.
Risk Factors
Manufacturing complexity of patient‑specific drugs, regulatory uncertainty for individualized biologics, and competition from other personalized cancer therapies.
Competitive Landscape
Competes with neoantigen vaccines, bispecific antibodies, and CAR‑T therapies; differentiated by its oligonucleotide‑based tri‑functional design that integrates direct cytotoxicity with immune activation.